23736 Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before July 

20, 2009 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: David A. Lambertson, 

Ph.D., Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–4632; Facsimile: (301) 402– 

0220; e-mail: lambertsond@od.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention concerns the use of 

tetrahalogenated thalidomide 

derivatives for the treatment of cancer. 

Thalidomide has been shown to be a 

potent inhibitor of angiogenesis (the 

formation of new blood vessels). The 

popular belief is that angiogenesis 

enhances tumor formation by providing 

tumors with increased nutrients, 

allowing their sustained growth. 

However, thalidomide is a natural 

teratogen that can cause severe birth 

defects, and has a propensity towards 

causing neotropenia and deep venous 

thrombosis in recipients of the drug. 

This led researchers to seek out safer 

derivatives of thalidomide that retain an 

anti-cancer activity. The 

tetrahalogenated derivatives disclosed 

by this technology may represent both a 

safer alternative to thalidomide and 

potentially a more successful alternative 

to the angiogenesis inhibitors currently 

being clinically tested. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: May 12, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–11680 Filed 5–19–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: The Manufacture, Use, 

Distribution of and Sale of Fused 

Azepinone Cyclin Dependent Kinase 

Inhibitors as Therapeutics 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent No. 6,610,684 

entitled, ‘‘Fused Azepinone Cyclin 

Dependent Kinase Inhibitors’’ and all 

foreign counterparts [HHS Ref. No. 

E–025–1998/0] to ShanaRx 

Pharmaceuticals. The patent rights in 

this invention have been assigned to the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the use 

of the Cyclin Dependent Kinase 

Inhibitors and their methods of use in 

the Licensed Patent Rights for the 

treatment of: (i) Disorders caused by 

damage, injury, infection in or abnormal 

function of the peripheral or central 

nervous system including pain, 

neuropathy, retinal degeneration, 

glaucoma, Alzheimer’s disease, 

Parkinson’s disease, ALS, depression, 

schizophrenia, and anxiety; (ii) 

disorders caused by damage, injury, 

infection in or abnormal function of 

cerebral vasculature and cardiac 

vasculature including cardiac failure 

and myocardial infections; (iii) cancer 

and neoplastic disorders; (iv) 

inflammatory and autoimmune diseases 

including Multiple Sclerosis; and (v) 

endocrine and neuroendocrine 

disorders including Diabetes Mellitus. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

August 18, 2009 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated co-exclusive license 

should be directed to: Whitney A. 

Hastings, M.S., Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804. Telephone: 

(301) 451–7337; Facsimile: (301) 402– 

0220; E-mail: hastingw@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention describes a class of cyclin 

dependent kinase (CDK) inhibitors that 

have anti-proliferative activity in human 

tumor cell lines. CDKs are important in 

the control of the cell cycle and 

alterations in CDK expression, function, 

or regulation are associated with 

diseases characterized by cellular 

proliferation. Increasing CDK activity 

has been reported in many cancers and 

observed in a wide variety of primary 

human tumors and human tumorderived cell lines, including lung, 

breast, brain, bone, skin, bladder, 

kidney, ovary, liver, colon, pancreas as 

well as in leukemia. The compounds of 

this invention have also been found to 

potently inhibit GSK3beta activity. 

Some of compounds of this invention 

have been shown to be more potent 

towards the GSK3beta target than 

towards CDKs. The GSK3beta enzyme, a 

proline-directed serine-threonine 

kinase, has been linked to a variety of 

cellular processes and several disparate 

areas of biology. Thus, this technology 

could provide therapeutic opportunities 

for a variety of indications, including 

Alzheimer’s, neurological disorders, and 

cardiac failure. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within ninety (90) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 23737 

Dated: May 12, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–11681 Filed 5–19–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Agency Information Collection 

Activities: Free Admittance Under 

Conditions of Emergency 

AGENCY: U.S. Customs and Border 

Protection (CBP), Department of 

Homeland Security. 

ACTION: 60-Day notice and request for 

comments; Extension of an existing 

information collection: 1651–0044. 

SUMMARY: As part of its continuing effort 

to reduce paperwork and respondent 

burden, CBP invites the general public 

and other Federal agencies to comment 

on an information collection 

requirement concerning the Free 

Admittance Under Conditions of 

Emergency. This request for comment is 

being made pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). 

DATES: Written comments should be 

received on or before July 20, 2009, to 

be assured of consideration. 

ADDRESSES: Direct all written comments 

to U.S. Customs and Border Protection, 

Attn: Tracey Denning, Office of 

Regulations and Rulings, 799 9th Street, 

NW., 7th Floor, Washington, DC 20229– 

1177. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information 

should be directed to Tracey Denning, 

U.S. Customs and Border Protection, 

Office of Regulations and Rulings, 799 

9th Street, NW., 7th Floor, Washington, 

DC 20229–1177, at 202–325–0265. 

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L 104–13; 

44 U.S.C. 3505(c)(2)). The comments 

should address: (a) Whether the 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimates of the burden of the 

collection of information; (c) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; (d) 

ways to minimize the burden including 

the use of automated collection 

techniques or the use of other forms of 

information technology; and (e) 

estimates of capital or start-up costs and 

costs of operations, maintenance, and 

purchase of services to provide 

information. The comments that are 

submitted will be summarized and 

included in the request for Office of 

Management and Budget (OMB) 

approval. All comments will become a 

matter of public record. In this 

document the CBP is soliciting 

comments concerning the following 

information collection: 

Title: Free Admittance Under 

Conditions of Emergency. 

OMB Number: 1651–0044. 

Form Number: None. 

Abstract: This collection of 

information will be used in the event of 

emergency or catastrophic event to 

monitor goods temporarily admitted for 

the purpose of rescue or relief. 

Current Actions: There are no changes 

to the information collection. This 

submission is being made to extend the 

expiration date. 

Type of Review: Extension (without 

change). 

Affected Public: Nonprofit Assistance 

Organizations. 

Estimated Number of Respondents: 1. 

Estimated Time Per Respondent: 1 

hour. 

Estimated Total Annual Burden 

Hours: 1. 

Dated: May 14, 2009. 

Tracey Denning, 

Agency Clearance Officer, Customs and 

Border Protection. 

[FR Doc. E9–11754 Filed 5–19–09; 8:45 am] 

BILLING CODE 9111–14–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5281–N–36] 

Disaster Housing Assistance ProgramIke (DHAP-Ike Grant Agreement) 

AGENCY: Office of the Chief Information 

Officer, HUD. 

ACTION: Notice. 

SUMMARY: The proposed information 

collection requirement described below 

has been submitted to the Office of 

Management and Budget (OMB) for 

review, as required by the Paperwork 

Reduction Act. The Department is 

soliciting public comments on the 

subject proposal. 

In August and September 2008, 

Hurricanes Ike and Gustave struck the 

United States causing catastrophic 

damage. On September 23, 2008, HUD 

and FEMA executed an Interagency 

Agreement under which HUD shall act 

as the servicing agency of DHAP-Ike. 

The paperwork involved in this action 

all activities related to DHAP-Ike from 

execution of the grant agreement to case 

management. 

DATES: Comments Due Date: June 19, 

2009. 

ADDRESSES: Interested persons are 

invited to submit comments regarding 

this proposal. Comments should refer to 

the proposal by name and/or OMB 

approval Number (2577–0258) and 

should be sent to: HUD Desk Officer, 

Office of Management and Budget, New 

Executive Office Building, Washington, 

DC 20503; fax: 202–395–6974. 

FOR FURTHER INFORMATION CONTACT: 

Lillian Deitzer, Reports Management 

Officer, QDAM, Department of Housing 

and Urban Development, 451 Seventh 

Street, SW., Washington, DC 20410; 

e-mail Lillian Deitzer at 

Lillian_L._Deitzer@HUD.gov or 

telephone (202) 402–8048. This is not a 

toll-free number. Copies of available 

documents submitted to OMB may be 

obtained from Ms. Deitzer. 

SUPPLEMENTARY INFORMATION: This 

notice informs the public that the 

Department of Housing and Urban 

Development has submitted to OMB a 

request for approval of the Information 

collection described below. This notice 

is soliciting comments from members of 

the public and affecting agencies 

concerning the proposed collection of 

information to: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information; (3) Enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) Minimize the 

burden of the collection of information 

on those who are to respond; including 

through the use of appropriate 

automated collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

This notice also lists the following 

information: 

Title of Proposal: Disaster Housing 

Assistance Program-Ike (DHAP-Ike 

Grant Agreement). 

OMB Approval Number: 2577–0258. 

Form Numbers: None. 

Description of the Need for the 

Information and its Proposed Use: